What primary outcomes, subjective and objective risk factors, and study design elements (including title, inclusion and exclusion criteria, and secondary outcomes) should be used for a retrospective cohort study of metabolic‑associated steatohepatitis progressing to cirrhosis in an obesity‑predominant community hospital?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 1, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Retrospective Study Design for MASLD Progression to Cirrhosis in an Obesity-Predominant Community Hospital

Proposed Study Title

"Risk Factors and Clinical Outcomes of Metabolic Dysfunction-Associated Steatotic Liver Disease Progression to Cirrhosis in a High-Prevalence Obesity Community: A Retrospective Cohort Study"

Primary Outcomes

Your primary outcome should be progression to cirrhosis or liver-related mortality, as fibrosis stage is the strongest predictor of outcomes in MASLD 1. Specifically:

Primary Outcome (Choose ONE):

  • Development of cirrhosis (defined by imaging, biopsy, or clinical decompensation) during follow-up period
  • Composite endpoint: Liver-related mortality, hepatocellular carcinoma (HCC), or hepatic decompensation (ascites, variceal bleeding, hepatic encephalopathy)

Rationale: The 2024 EASL-EASD-EASO guidelines clearly state that fibrosis stage is the strongest predictor of liver-related mortality and HCC risk in MASLD 1. In individuals with MASH, liver-related mortality is as high as 25.6/1,000 person-years, making this the most clinically meaningful outcome 1.

Secondary Outcomes

Based on the evidence showing MASLD's systemic impact 1:

  1. All-cause mortality (MASLD increases mortality by 17.05/1,000 person-years 1)
  2. Cardiovascular events (myocardial infarction, stroke, heart failure - HR 1.40 for non-fatal CVD 1)
  3. Development of hepatocellular carcinoma
  4. Progression of fibrosis stage (if serial non-invasive assessments available)
  5. Development of type 2 diabetes (in those without diabetes at baseline)
  6. Chronic kidney disease development (HR 1.43 in MASLD 1)
  7. Hospital admissions for liver-related complications

Inclusion Criteria

Be specific and capture your high-risk population 1:

  1. Age ≥18 years at baseline
  2. Documented MASLD diagnosis by:
    • Imaging evidence of hepatic steatosis (ultrasound, CT, or MRI showing ≥5% liver fat) OR
    • Elevated liver enzymes (ALT >33 U/L males, >25 U/L females 1) with metabolic risk factors OR
    • Liver biopsy showing steatosis
  3. At least one cardiometabolic risk factor:
    • BMI ≥25 kg/m² (or ≥23 kg/m² for Asian populations 1)
    • Type 2 diabetes mellitus
    • Hypertension
    • Dyslipidemia (hypertriglyceridemia or low HDL)
  4. Minimum follow-up of 2 years with available medical records
  5. Baseline assessment between [specify years, e.g., 2015-2020]

Exclusion Criteria

Critical to isolate MASLD from other liver diseases 1:

  1. Other causes of chronic liver disease:
    • Viral hepatitis (HBV, HCV - check serology)
    • Autoimmune hepatitis (check ANA, ASMA, immunoglobulins)
    • Primary biliary cholangitis or primary sclerosing cholangitis
    • Hemochromatosis (check ferritin, transferrin saturation)
    • Wilson's disease
    • Alpha-1 antitrypsin deficiency
  2. Significant alcohol consumption:

    • 20 g/day for females

    • 30 g/day for males

  3. Hepatotoxic medication use (amiodarone, methotrexate, tamoxifen, valproate)
  4. Pregnancy during study period
  5. Prevalent cirrhosis at baseline (if studying progression TO cirrhosis)
  6. Incomplete medical records preventing outcome assessment
  7. Prior liver transplantation

Risk Factors to Collect (Objective & Subjective)

Objective Risk Factors (Strongest Predictors per Guidelines 1):

Metabolic Parameters (Most Critical):

  • Type 2 diabetes status - THE most important determinant of fibrosis progression and HCC 1
  • Obesity metrics:
    • BMI at baseline and follow-up
    • Waist circumference (>94 cm males, >80 cm females for Caucasians 1)
    • Weight change over time (>5 kg gain associated with fibrosis progression 1)
  • Hypertension (associated with fibrosis progression 1)
  • Dyslipidemia (particularly hypertriglyceridemia - strongest MASLD predictor OR 3.11 2)

Laboratory Values:

  • Baseline liver enzymes: ALT, AST (use lower thresholds: ALT >33 U/L males, >25 U/L females 1)
  • Fibrosis markers:
    • FIB-4 score (age, AST, ALT, platelet count) - first-line tool 3
    • NAFLD Fibrosis Score if available
    • AST/ALT ratio
  • Metabolic markers:
    • Fasting glucose, HbA1c
    • Lipid panel (triglycerides, HDL, LDL)
    • Insulin resistance markers if available (HOMA-IR)
  • Platelet count (thrombocytopenia indicates advanced fibrosis)
  • Albumin, bilirubin, INR (liver synthetic function)

Imaging/Non-invasive Tests:

  • Transient elastography (FibroScan) results if available
  • Imaging findings: degree of steatosis, cirrhosis features, portal hypertension signs
  • Presence of varices on endoscopy

Demographic Factors (Per Guidelines 1):

  • Age (older age increases risk)
  • Sex (males >50 years at higher risk 1)
  • Menopausal status in women (postmenopausal = higher risk 1)
  • Ethnicity (Hispanic ethnicity increases risk 1)

Subjective/Clinical Risk Factors:

  1. Duration of obesity (longer duration = worse outcomes 1)
  2. Duration of diabetes (major determinant 1)
  3. Physical activity level (insufficient activity OR 1.42 for MetS 2)
  4. Sleep quality and duration (poor sleep quality OR 1.37 4)
  5. Dietary patterns (Mediterranean diet protective 5)
  6. Medication history:
    • Metformin, GLP-1 agonists (potentially protective)
    • Statins
    • Antihypertensives
  7. Family history of liver disease, diabetes, obesity
  8. Socioeconomic factors (lower SES associated with worse outcomes 1)
  9. Comorbidities:
    • Obstructive sleep apnea
    • Chronic kidney disease
    • Cardiovascular disease history

Study Design Algorithm

Step 1: Patient Identification

  • Query electronic health records for patients with:
    • ICD codes for NAFLD/MASLD/hepatic steatosis
    • Elevated liver enzymes + metabolic risk factors
    • Imaging reports mentioning steatosis
    • BMI ≥30 kg/m² (given your 80% morbid obesity population)

Step 2: Apply Inclusion/Exclusion Criteria

  • Screen for other liver diseases (viral hepatitis serology, autoimmune markers)
  • Verify alcohol consumption <threshold
  • Confirm minimum 2-year follow-up

Step 3: Baseline Data Collection

  • Extract all objective risk factors listed above
  • Calculate FIB-4 score at baseline
  • Stratify by fibrosis risk: low (<1.3), intermediate (1.3-2.67), high (>2.67) 3

Step 4: Outcome Ascertainment

  • Review records for cirrhosis diagnosis (imaging, biopsy, clinical decompensation)
  • Document liver-related events (HCC, variceal bleeding, ascites, encephalopathy)
  • Record mortality and cause of death
  • Capture cardiovascular events

Step 5: Statistical Analysis Plan

  • Univariate analysis: Compare progressors vs. non-progressors for each risk factor
  • Multivariable Cox regression: Adjust for confounders
    • Model 1: Age, sex, BMI, diabetes
    • Model 2: Add FIB-4, ALT, metabolic syndrome components
    • Model 3: Add duration of obesity/diabetes, weight change
  • Stratified analyses: By diabetes status, obesity severity, baseline fibrosis stage
  • Time-to-event analysis: Kaplan-Meier curves for cirrhosis development

Critical Pitfalls to Avoid

  1. Normal ALT does not exclude significant disease - 22% of MASLD patients with normal aminotransferases can have significant steatohepatitis and develop cirrhosis 1. Don't rely solely on liver enzymes.

  2. Fibrosis stage trumps everything - The guidelines are unequivocal: fibrosis stage is THE strongest predictor of outcomes 1. Prioritize collecting FIB-4 scores or elastography data.

  3. Diabetes is not just another risk factor - T2D has the greatest impact on natural history, with 4-fold increased risk of death and 2-fold increased liver-related outcomes 1. Analyze diabetic vs. non-diabetic cohorts separately.

  4. Multiple metabolic hits matter - Each additional cardiometabolic risk factor leads to stepwise increase in cirrhosis/HCC risk 1. Count the number of metabolic risk factors per patient.

  5. Don't ignore cardiovascular outcomes - MASLD patients have HR 1.40 for non-fatal CVD 1. In your obese population, cardiovascular death may compete with liver-related mortality.

  6. Weight trajectory matters more than baseline weight - Weight gain >5 kg during follow-up predicts fibrosis progression 1. Capture serial weight measurements.

  7. Ethnicity affects risk - Hispanic ethnicity independently increases fibrosis progression risk 1. Document and adjust for ethnicity in your analysis.

Sample Size Considerations

Given your 80% obesity prevalence and community hospital setting, expect:

  • MASLD prevalence: 50-60% in overweight/obese 2
  • Advanced fibrosis: 7% in overweight MASLD 2, higher in your morbidly obese population
  • Progression rate: Approximately 20-30% over 5 years in high-risk patients 1

Aim for minimum 200-300 patients to detect meaningful associations with adequate power, assuming 20-30% event rate over your follow-up period.

Practical Implementation for Community Hospital

Your setting is ideal for this study because:

  • High obesity prevalence (80%) provides adequate exposure variability
  • Community hospitals capture real-world progression patterns
  • Retrospective design is feasible with existing EMR data

Prioritize collecting:

  1. FIB-4 scores (requires only age, AST, ALT, platelets - universally available 3)
  2. Diabetes status and duration (strongest modifiable predictor 1)
  3. Serial BMI measurements (weight change predicts progression 1)
  4. Baseline metabolic syndrome components (stepwise risk increase 1)

This design will generate clinically actionable data on which obese patients in your community are at highest risk for cirrhosis progression, informing targeted screening and intervention strategies.

References

Related Questions

What laboratory workup should be ordered for a patient with biliary colic and hepatic steatosis (fatty liver)?
What strategies prevent metabolic dysfunction-associated steatotic liver disease (MASLD) from progressing to cirrhosis?
How is metabolic disease-associated steatosis with moderate (stage 2) fibrosis classified?
Please provide a new draft of a study titled "Disease Progression and Liver‑Related Outcomes in Adults with Metabolic‑Dysfunction‑Associated Steatotic Liver Disease (MASLD): A Retrospective Analysis of Risk Factors and Natural History".
Can ramelteon (Rozerem) be combined with hydroxyzine for sleep, and what dosing and safety precautions are recommended, especially in older adults or patients with liver disease?
In an adult patient experiencing an infusion reaction, does the onset of throat pain require a change in management?
What is the recommended rate for titrating risperidone (Risperdal) in an inpatient hospital?
What is the most appropriate weight loss treatment for a 15-year-old boy?
What is the appropriate assessment and management plan for a patient presenting with neck pain?
What is the appropriate management and treatment regimen for typhoid fever and malaria?
For a 78-year-old male with uncontrolled type 2 diabetes mellitus (HbA1c 9.3%), albuminuria, and estimated glomerular filtration rate 79 mL/min/1.73 m² who refuses insulin therapy, what non‑insulin treatment options should be pursued?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.